Alteration of methotrexate uptake in human leukemia cells by other agents.
The uptake of methotrexate (MTX) and the effect of drugs known to either inhibit or enhance MTX transport in L1210 murine leukemia were studied in man using blast cells from patients with acute myelogenous leukemia in vitro. MTX uptake was found to proceed slowly, requiring at least 160 min for cells to reach a "steady state" when extracellular MTX concentrations were 1 muM. Efflux of MTX from preloaded cells required 80 to 120 min and the nonexchangeable or tightly bound fraction was 40% of the total intracellular drug. Utilizing doses that are estimates of achievable peak blood levels following single i.v. injection, cephalothin (21 mug/ml) and hydrocortisone (20 mug/ml) inhibited net MTX accumulation by 20 and 28%, respectively. Vincristine sulfate at 8.3 and 0.083 mug/ml enhanced MTX uptake by 54 and 33%, respectively, by inhibiting MTX efflux, thus increasing the level of intracellular drug in excess of the tightly bound fraction. The potential clinical implications of using MTX in combination with the aforementioned drugs for cancer chemotherapy are discussed.
D002512:Cephalothin / Q000494:pharmacology; D003864:Depression, Chemical; D006801:Humans; D006854:Hydrocortisone / Q000494:pharmacology; D066298:In Vitro Techniques; D015470:Leukemia, Myeloid, Acute / Q000378:metabolism*; D008727:Methotrexate / Q000378:metabolism*; D013268:Stimulation, Chemical; D013997:Time Factors; D014750:Vincristine / Q000494:pharmacology
D014750:Vincristine; D002512:Cephalothin; D006854:Hydrocortisone; D008727:Methotrexate